

Supplementary Materials for

SARS-CoV-2-Triggered Mast Cell Rapid Degranulation Induces Alveolar Epithelial Inflammation and Lung Injury

Meng-Li Wu¹, Feng-Liang Liu², Jing Sun³, Xin Li⁴, Xiao-Yan He^{2,7}, Hong-Yi Zheng², Yan-Heng Zhou⁴, Qihong Yan⁴, Ling Chen⁴, Guo-Ying Yu¹, Junbiao Chang¹, Xia Jin⁵, Jincun Zhao³, Xin-Wen Chen^{4,7*}, Yong-Tang Zheng^{2,7*}, Jian-Hua Wang^{4,6,*}

*Correspondence to:

J.-H, Wang, Email: wang_jianhua@gibh.ac.cn

Y.-T, Zheng, Email: zhengyt@mail.kiz.ac.cn

X.-W, Chen, Email: Chen_xinwen@gibh.ac.cn

This PDF file includes:

Figure S1 to S7

Table S1




Figure S1. Virus distribution in SARS-CoV-2-infected humanized mice. C57BL/6N-Ace2^{em2(hACE2-WPRE,pgk-puro)/CCLA} mice were intranasally infected with SARS-CoV-2 (strain 107) at a dose of 2×10^6 TCID₅₀, and were euthanized at the 1 dpi and 3 dpi. Lung sections were stained with anti-nucleocapsid antibody (red) and DAPI (blue).




Figure S2. SARS-CoV-2 induces mast cell degranulation and lung injury in Ad5-hACE2-transduced BALB/c mice.

Five Mice were transduced with 2.5×10^8 FFU of Ad5-hACE2 in 75 mL of DMEM intranasally, 5 days later, mice received 7×10^4 TCID₅₀ of SARS-CoV-2. Two mice were used as the mock-infections. The lungs were collected at 2 dpi, 4 dpi, and 6 dpi. Toluidine blue staining was used to observe MCs and their

degranulation (a, c, e and g), and the lung injury was observed by H.E. staining (b, d, f, h). Scale bar: 100 μ m. (i)The pathological score was assessed according to the degree of lung tissue lesions and MC count in lung sections was calculated. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$ are considered significant differences.




Figure S3. SARS-CoV-2 infection of LAD2 cells.

(a) LAD2 cells were infected with SARS-CoV-2 (strain 2019-nCoV WIV04) (M.O.I. =1) for the indicated time, and the cellular levels of nucleocapsid mRNA were quantified with q(RT-)PCR. Data are normalized to β -actin mRNA and expressed as $-\Delta Ct$ values. (b) LAD2 and Huh-7 cells (1×10^5) were infected with SARS-CoV-2 Spike-pseudotyped lentivirus (NL4-4/S) (5 ng p24^{gag}) for 72 h, and viral infection was determined by measuring the luciferase activity. One representative data from 3 independent repeats are shown (a, b). Data are presented as mean \pm SD. *** $p < 0.001$ and **** $p < 0.0001$ are considered significant differences.




Figure S4. Assay for LAD2 cell degranulation.

LAD2 cells were treated with or without Spike-RBD (a) or nucleocapsid protein (b) (5 $\mu\text{g/ml}$ each) of SARS-CoV-2 at 37°C for the indicated time, then cells were permeabilized and immunostained with anti-avidin-FITC at 4°C for 1 h, and analyzed with flow cytometry. One representative result from 7 repeats is shown. MFI: mean fluorescence intensity (a, b).




Figure S5. Cytokine profile in LAD2 cells.

LAD2 cells were treated with or without Spike-RBD (5 µg/ml) at 37°C for the indicated time, and the mRNA levels of IL-6, IL-8, IL-1β and TNF-α were quantified with q(RT-) PCR, and normalized to *gapdh* mRNA. One representative result from 3 repeats is shown. Data are presented as mean ± SD. * p<0.05, ** p<0.01, *** p<0.001 and ****p<0.0001 are considered significant differences.




Figure S6. Cytokine productions in A549 cells.

LAD2 cells were prior-treated with or without Lor. (5 µg/mL) or Eba. (3 µg/mL) for 20 h, then cells were treated with Spike-RBD (5 µg/ml) for 2 h, and the culture supernatants were harvested to treat A549 cells for additional 24 h, or A549 cells were directly treated with or without Spike-RBD for 24 h. The productions of IL-6, IL-8, and IL-1β were measured with intracellular immunostaining with specific antibodies. One representative result from 3 repeats is shown. MFI: mean fluorescence intensity.




Figure S7. Cytokine expression in H1299 cells.

LAD2 cells were treated with Spike-RBD (5 $\mu\text{g}/\text{ml}$) for 2 h, and the culture supernatants were harvested to treat H1299 cells for additional 24 h, and the mRNA levels of IL-6, TNF- α , IL-8 and IL-1 β were quantified with real time q(RT-) PCR, and normalized to *gapdh* mRNA. One representative result from 3 repeats is shown. Data are presented as mean \pm SD. ** $p < 0.01$ and *** $p < 0.001$ are considered significant differences.

Human IL-6	Forward:	5'-CAG ACA GCC ACT CAC CTC TTC AG-3'
	Reverse	5'-CAG CCA TCT TTG GAA GGT TCA G-3'
Human TNF-α	Forward:	5'-CCC AGG CAG TCA GAT CAT CTT C-3'
	Reverse	5'-GTG AGG AGC ACA TGG GTG GAG-3'
Human IL-1β	Forward:	5'-CGT CAG TTG TTG TGG CCA TGG A-3'
	Reverse	5'- GAG CGT GCA GTT CAG TGA TCG TA-3'
Human IL-8	Forward:	5'-CTG ATT TCT GCA GCT CTG TGT GA-3'
	Reverse	5'-GGT CCA GAC AGA GCT CTC TTC CA-3
Human CCL20	Forward:	5'-GCT GCT TTG ATG TCA GTG CT-3'
	Reverse	5'-TGT CAC AGC CTT CAT TGG C-3'
Human CCL5	Forward:	5'-ACC ACA CCC TGC TGC TTT G-3'
	Reverse	5'-GCG GTT CTT TCG GGT GAC A-3'
Human MMP9	Forward:	5'-CCT TCT ACG GCC ACT ACT GTG C-3'
	Reverse	5'-GCC AGT ACT TCC CAT CCT TGA AC-3'
Human MMP19	Forward:	5' -GCA ATG TGGC TCC CTT GAC-3'
	Reverse	5' -TCA GTC CAG AAC TCG TCT TCG-3'
Human GAPDH	Forward:	5'-ATC CCA TCA CCA TCT TCC AGG-3'
	Reverse	5'-CCT TCT CCA TGG TGG TGA AGA C-3'
Mouse IL-6	Forward:	5'-CTT CCA TCC AGT TGC CTT CTT G-3'
	Reverse	5'-AAT TAA GCC TCC GAC TTG TGA AG-3'
Mouse TNF-α	Forward:	5'-CAG ACC CTC ACA CTC AGA TCA TCT-3'
	Reverse	5'- CCT CCA CTT GGT GGT TTG CTA-3'
Mouse IL-1β	Forward:	5'- CTT TCA GAG GCC AGA GAG TCC-3'
	Reverse	5'- TCC CTG TAG TGA CAG CAC CT3'
Mouse IL-8	Forward:	5'-CGG CAA TGA AGC TTC TGT AT-3'
	Reverse	5'-CCT TGA AAC TCT TTG CCT CA-3'
Mouse INFγ	Forward:	5'- ATG AAC GCT ACA CAC TGC ATC-3'
	Reverse	5'- CCA TCC TTT TGC CAG TTC CTC-3'
Mouse CRF	Forward:	5'- CAG AGA TTC CTG AGG CTC CAA CA-3'
	Reverse	5'- AGT CAC CGC CAT ACG AGT CCT G-3'
Mouse CCL20	Forward:	5'-AAG ACA GAT GGC CGA TGA AG-3'
	Reverse	5'-AGG TTC ACA GCC CTT TTC AC-3'
Mouse CCL5	Forward:	5'-GTG CCC ACG TCA AGG AGT AT-3'
	Reverse	5'-GGG AAG CTA TAC AGG GTC A-3'
Mouse GAPDH	Forward:	5'- TGC ACC ACC AAC TGC TTA G-3'
	Reverse	5'- GAT GCA GGG ATG ATG TTC-3'
SARS-CoV-2 nucleocapsid	Forward:	5'-GGG GAA CTT CTC CTG CTA GAA T-3'
	Reverse	5'-CAG ACA TTT TGC TCT CAA GCT G-3'
	TaqMan probe	5'-FAM-TTG CTG CTG CTT GAC AGA TT-TAMRA-3'

Table S1. The primers and probes for (RT-) PCR